Biomedcode
Company Profile
Biomedcode Hellas SA is a highly innovative Contract Research Organization (CRO) founded in 2006 as a spin-off company of the Biomedical Sciences Research Centre "Alexander Fleming”. Biomedcode offers a diverse array of state-of-the-art preclinical evaluation platforms based on a unique collection of spontaneous and induced humanized mouse models that closely recapitulate the pathology and complexity of human inflammatory diseases including Rheumatoid Arthritis, Osteoporosis, Intestinal Inflammation, Multiple Sclerosis, Psoriasis and others. The proprietary spontaneous and induced humanized mouse disease models offered by Biomedcode in combination with technological platforms for comprehensive phenotyping of disease progression and response to therapy form the tools offered by Biomedcode for the accurate, reproducible and sensitive evaluation of human therapeutics.
Since 2006, Biomedcode has provided preclinical drug evaluation services to more than 80 pharmaceutical and biotech companies worldwide contributing in the preclinical evaluation of multiple human therapeutics including novel biologics, biosimilars, biobetters and small molecules while data generated by Biomedcode have been included in patent applications and contributed in several successful IND process applications.
In addition to its preclinical services, Biomedcode maintains a highly active R&D programme that aims to generate, standardise and commercialize novel humanized preclinical evaluation platforms that are also used to identify disease pathways and biomarkers through pharmacogenomic and metabonomic approaches. Recently, Biomedcode has introduced activities that also cover disease induced phenotyping of genetically modified mouse models, repositioning approaches and the inclusion of comorbidities in the evaluation of test therapeutics. Through its research activities Biomedcode is a partner of choice in a number of national and European funded research activities thus strengthening its ties to the academic community and networks of innovative research.
